assay, (d) specific proaccelerint assay. The common procedure is to time the clotting at 370 C. after adding 0.2 ml. Ca-tpln. to the various plasma mixtures. "Ca-tpln." is equal vols. of 0.02 M CaCI2 and tissue thromboplastin, the preferred preparation being "soluplastin,"* since our tests show this to be free from (pro)convertin and (pro)-accelerin contaminants. The respective "substrates" are: (a) for PT test (cf."), simply 0.1 ml. of patient's plasma (pp) ; (b) for prothrombin assay (cf.'), 0.1 ml. 1: 10 pp (sal. dil.) plus 0.1 ml. proconvertin'3-enriched beef BaSO4-plasma; (c) for proconvertin assay (cf.'0), 0.1 ml. 1: 10 pp plus "asbestos-filtered" beef plasma; (d) for proaccelerin assay (cf.'), 0.1 ml. 1: 10 BaSO4-pp plus "aged" human normal plasma. The principle is that each substrate supplies all the necessary clotting factors except the one being assayed.
"Nornial" standards, reference (dilution) curves, and reagent checks for these and other tests involve much meticulous experimentation. They permit assays in terms of "per cent" of normal, in each case, whether a reference curve is used or a statistical norm for an empirical (e.g., 2-stage prothrombin) unitage. A known normal is assayed with each group of tests to orient the standard to any change of reagents or test conditions. BaSO4 adsorption, of plasma, serum, or fibrinogen solutions, is effected by mixing with powdered BaSO4 (Merck's), 0.1 gm. per ml., for 10 minutes at 37°C. and centrifuging off the sediment. This sediment may be eluted with ½3 vol. of 0.2 M sod. citrate for a new specific 2-stage prothrombin assay (Method III) First, incubate 0.1 ml. eluate with 3.7 ml. saline (0.85% NaCl), 1 ml. imidazole buffer (pH: 7.3), 0.1 ml. accelerin (BaCO3-adsorbed beef serum,' 1: 8 dil.), 0.1 ml. beef proconvertin (cf."8), 0.5 ml. "soluplastin," 0.5 ml. 0.15 M CaCl2. Secondly, time the clotting, at 280 C., of 0.2 ml. fibrinogen with 0.2 ml. samples of incubate at successive minute intervals. Clotting-times are referred to a standard normal eluate dilution curve to assay prothrombin as "percentage" (of normal). Like the orthodox 2-stage (Method II), the new test activates the prothrombin (but in the fibrinogen-free eluate) to thrombin, which is then measured by the shortest clotting-time for a standard fibrinogen. The end-point is usually reached within 5 minutes and is typically stable (unlike II), indicating absence of thrombin-inactivating inhibitors. Other differences from the orthodox two-stage are non-use of acacia, employment of a fixed dilution, and a different mode of computation.
The orthodox 2-stage (Method II) for specific prothrombin assay: Defibrination of plasma is effected by collecting fibrin on a glass rod for 15 minutes after adding 0.1 ml. thrombin to 0.5 ml. plasma plus 0.4 ml. saline. The bovine thrombin of the Upjohn Co., supplied through the courtesy of Dr. J. T. Correll, is very satisfactory when used in a strength of 20 "units" per ml. Dilution of the defibrinated plasma is (IIa) with saline, in the "original"2" method, (IIb) with 1:150 saline dil. BaCO3-adsorbed beef serum (AcG or accelerin) in the "modified"' method, and (IIc) with AcG plus 1:100 beef proconvertin (ProC)"8 in our "improved" method. Activation of the suitably diluted defibrinated plasma is by incubation of 0.6 ml. with 1.8 ml. of (a) Difco's "prothrombin incubation mixture," supplied through the courtesy of Dr. C. W.
Christensen, or (b) our own preferred "mix" (cf.'), viz. 23 saline, 2 Figure 1 . In all these cases there was an abnormally high (100-300%,) proaccelerin.
Granting, then, that the three "specific" methods all measure the same clotting component, what is the evidence that this is indeed prothrombin? One direct answer was given by J ohnson and Ferguson,"2 who used Method II to show excellent analytical recoveries of purified prothrombin added to normal human plasma.
Effects of technical variables, including those dependent on reagents. The present study confirms an earlier report2" that Method II is very dependent upon technical variables as far as any "absolute" unitage is concerned. Clotting-times are affected by temperature, pH, ionic strength and nature of salts, etc., present, and by such "fibrinoplastic" additives as the acacia." our total series. However, the major determinant of the absolute unitage is the "reactivity" of the standard fibrinogen. The linear correlation (Fig. 2) between Method II unitage and known plasma dilutions (using BaSO4 plasma as diluent) extends to the practical limits of the test.
Variation in the type of diluent, in step 2 of Method II, was re-studied. In the above 10 repeat determinations on a single fresh human plasma, tests made with simple saline diluent (a) gave 353 (330-398, (X: 5.7%) s FERGUSON, LEWIS, FRESH method. Table 1 shows parallel determinations on known plasma dilutions, using as diluents: (i) AcG+ProC, (ii) AcG, (iii) ProC, (iv) saline only.
The fact that there was only a slight improvement on adding the accelerin and proconvertin may be attributed to the fact that these agents were already sufficient in the fresh normal plasma tested. In these and many other comparative studies the "improved" (IIc) and the "modified" (Ilb) tests agreed closely, with the former usually giving a few extra units. 1950 , but we kept some of her frozen plasma and three years later were able to prove its normal prothrombin (but absence of proconvertin). This required our specific tests, however. Thus, the usual AcG-"modified" 2-stage gave prothrombin as 34% (of normal), whereas our "improved" (ProC+AcG) method raised this to 857%, acceptably "normal" on a three-year-old plasma specimen. Moreover, the new test required a normal 4 minutes, instead of the other's 10 minutes for optimal activation. R. S., a 32-year-old white male, returned for another study in 1953 and also gave specific proconvertin assay of zero and the following variants of the 2-stage prothrombin assay, made on a 3-day-old plasma specimen (kept at -20°C.) : (i) with saline diluent, 33%, after 37 minutes ( !) activation; (ii) with AcG, 87%, after 10 minutes activation; (iii) with ProC (and saline), 79%o, after 16 minutes activation; (iv) with ProC plus AcG, 103% in a normal 3 minutes activation.
Clearly these two cases (included in Table 2 ) are congenital hypoproconvertinemtics, with essentially normal levels of prothrombin. Both gave very long "prothrombin time" tests (2%c of normal) and could not have been diagnosed without the use of proconvertin.
The acquired hypoproconvertinemtia cases in our series are almost invariably accompanied by hypoprothrombinemia and some associations are (a) normal infancy (newborn cord bloods) ,'1 (b) liver disease, (c) vitamin K deficiency (infants), (d) cases on dicumarol or tromexan therapy. The course of these cases can be followed either with the specific methods or with the prothrombin time test. In all of them the hypoproconvertinemia is moderate and our "improved" Method II prothrombin assay does not show significant differences from the ordinary "modified" 2-stage. Figure 4 shows the results of these two We have not encountered any case of genuine congenital hypoprothromlbinemtia, and the existence of such a state has even been questioned.'
The "improved" and "modified" 2-stage prothrombin methods have been found equally reliable on all other types of bleeding disorders. The latter method wvas used in the selected cases of Table 2 , but in the two cases of hypoproconvertinemia (see above), corrected values (marked with asterisks) were by the "improved" method. This table also illustrates another use of the 2-stage method, namely, in estimating prothrombin consumption, although for this test the simplicity of our 1-stage (Method I) is to be preferred. High serum prothrombin values, indicating defective prothrombin consumption, are noted in hemophilia (AHF deficiency)' or hemophilialike disorders, viz., PTC-deficiency,"" PTA-deficiency,23 and "4th. (D) factor"24 lack. Table 2 shows the normal plasma-but abnormal serumprothrombin levels in typical cases of three of these diseases. A hemophiliac (W.C.) and a PTC-deficient patient (for several months, R. J.) showed circulating inhibitors following transfusion therapy,"7 but these did not significantly interfere with the prothrombin determinations. Another ("idiopathic") case (L.T.) with circulating anticoagulant gave a somewhat low plasma prothrombin assay. Their prothrombin time tests were fairly normal, however.
Heparin is a natural (but probably pathological) anticoagulant, which the originators' of the 2-stage prothrombin method considered to interfere In parallel tests, with and without heparin, the strength of thrombin used in the defibrination was also varied. The finding of an anomalous elevation in the prothrombin unitage occurred in the heparinized samples only when the thrombin was unduly strong. It never exceeded the unitage with optimal strength thrombin (without heparin). It is suggested that there is an optimal strength for the thrombin used in the defibrination step of the assay. WVhen the thrombin is too strong, a little heparin (which, with plasma cofactor, is inhibitory to thrombin) can correct this. Radiation sickness. An addition to the literature2 on the subject of radiation hemorrhage is the human case (R. T.) presented in Table 4 . This elderly male had liver carcinoma metastasizing from a primary site in the colon and was under treatment with radiogold (Au198) at the Oak Ridge Hospital (ORINS) when we made the cited tests, reproduced (with permission) in Table 4 . The studies made on the day before the Au198 injection showed a normal plasma prothrombin but deficient prothrombin consumption. Residual (1 hour) serum percentage is stated. By the 4th day, prothrombin consumption was back to normal and remained so until the 19th day, becoming increasingly defective until the 22d day; the patient died next day from a massive hemorrhage at the primary carcinoma site. Plasma prothrombin levels fluctuated but were abnormally low only terminally. The last two observations of diminished prothrombin consumption 
CONCLUSIONS
Technical study and clinical laboratory use attest the value of the twostage assay as a true measure of prothrombin in plasma and in serum. The test must be "modified" to ensure adequacy of (pro)accelerin and, in severe deficiencies, of (pro)convertin also. Clinical applications here illustrated include (i) differential diagnosis of genuine hypoprothrombinemias (even in "mixed" deficiencies) from cases lacking the "accessory" factors, namely, proconvertin or proaccelerin; (ii) the following of the course of prothrombin levels in disease and after giving "hypoprothrombinemic" (dicumarol, tromexan, etc.) drugs and vitamin K; (iii) also, the following of prothrombin levels in infancy; (iv) the establishing of the essential normality of the plasma prothrombin level in afibrinogenemia (congenital), hypoproaccelerinemia ("parahemophilia"), hypoproconvertinemia (SPCA deficiency), hemophilia, PTC-' and PTA-23, etc.24 deficiencies, thrombocytosis, thrombocytopenia, thrombocytopathias, vascular purpuras, and radiation sickness (except terminally). Heparin and perhaps certain other pathological inhibitors of clotting may present some technical problems in these tests. The prothrombin time test is affected by some factors other than prothrombin but is valuable if this does not confuse the issue. The prothrombin consumption test is another application of "specific" prothrombin assay methods. The list of hemorrhagic disorders accompanied by defects in prothrombin consumption has a common denominator, namely, some cause of delayed or incomplete prothrombin activation. Taken with other modern tests of the blood-clotting mechanisms, the above techniques are of significant practical value in the elucidation of many bleeding and clotting disorders.
